Background: Access to vertical and transverse sections of a punch biopsy specimen improves the diagnosis of alopecia. Both two biopsy specimen and single-punch biopsy specimen techniques to visualize both transverse and vertical sections have been described. Their comparative diagnostic certainty is not known. We aimed to assess the diagnostic certainty of a modified HoVert (mHoVert) method, without direct immunofluorescence (DIF), compared to the St John's protocol, a two-biopsy technique with DIF.

Methods: Fifty-seven cases of alopecia processed using the St John's protocol and 60 cases of alopecia processed using mHoVert were reviewed. Diagnoses made were rated as certain/probable, possible, or uncertain, depending on the language in the histopathology report. Cases processed by the St John's protocol had final diagnosis and DIF result recorded.

Results: In the mHoVert group, significantly more diagnoses were certain/probable (66%, 95% confidence interval [CI]: 57%-75%), compared to 46% (95% CI: 36%-56%) of diagnoses in the St John's protocol group (p = 0.005). DIF result did not affect the final diagnosis in any of the 57 cases reviewed.

Conclusions: DIF is not required in the diagnosis of most cases of alopecia. The mHoVert method provides more certain/probable diagnoses than the St John's protocol and can reduce cost and patient morbidity.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.14447DOI Listing

Publication Analysis

Top Keywords

john's protocol
24
mhovert method
12
diagnostic certainty
12
biopsy specimen
12
cases alopecia
12
modified hovert
8
hovert mhovert
8
compared john's
8
alopecia biopsy
8
alopecia processed
8

Similar Publications

Endometrial cancer (EC) incidence and mortality have been steadily rising globally over recent decades. The introduction of advanced molecular technologies, such as next-generation sequencing (NGS) alongside the FIGO 2023 classification, presents opportunities for refined diagnostics and risk stratification. This study aimed to analyze differences in EC classification among oncology centers in southeastern Poland.

View Article and Find Full Text PDF

Background: The current standard of care (SoC) for patients with extensive-disease small-cell lung cancer (ED-SCLC) is chemo-immunotherapy. The efficacy of radiotherapy (RT) for chest consolidation has been established for patients with ED-SCLC who have responded to chemotherapy. There is a lack of data on incorporating RT as chest consolidation and metastasis-directed therapy for ED-SCLC.

View Article and Find Full Text PDF

Introduction: Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) may confer an increased risk for cardiovascular (CV) disease, including major adverse cerebro-cardiovascular events (MACE), deep vein thrombosis (DVT), and pulmonary embolism (PE). Patients with these conditions are often exposed for extended time periods to biologics, such as ixekizumab (IXE). Therefore, understanding the risk of CV events, especially MACE, in patients with PsO, PsA, and axSpA exposed to IXE is important.

View Article and Find Full Text PDF

Several international studies have investigated academic decision-making in higher education, but there is limited research on students' choice to study pharmacy in the Canadian context. While there is some variation across jurisdictions, decisions to enroll in a particular degree program fall into several decision-making domains (e.g.

View Article and Find Full Text PDF

Spine kinematics are commonly measured by external sensors such as motion capture and accelerometers. However, these skin-based measures cannot directly capture intervertebral motion of the lumbar spine. To date, research in this area has focused on the estimation of intervertebral kinematics using static trials but no study has analyzed agreement throughout the dynamic range of motion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!